Influence of norgestomet in combination with gonadotropins on induction of estrus and ovulation in prepubertal gilts.
Our objective was to determine whether priming with the progestogen norgestomet for 9 d would enhance estrual and ovulatory responses of prepubertal gilts to PG600 (400 IU eCG + 200 IU hCG). Gilts (140 to 190 d old) were assigned by litter, age, and weight to one of three treatments: 1) 9 d of norgestomet implant with an injection of PG600 after implant removal on d 9 (N+PG; n = 43); 2) no implant and an injection of PG600 on d 9 (PG; n = 36); or 3) neither implant nor PG600 (control; n = 29). Beginning on d 0, gilts were exposed once daily to a boar and checked until estrus was observed or until d 45 after the start of the experiment. Ovaries were examined for number of corpora lutea (CL) after estrus or at 45 d. Greater proportions of N+PG (63%, P < .05) and PG (69%, P < .01) gilts expressed estrus than did controls (34%), but proportions did not differ between N+PG and PG (P > .10). Among gilts in estrus following treatment with N+PG or PG, 100% showed estrus within 6 d after PG600 injection. For gilts that expressed estrus within 45 d, the average age at estrus was reduced (P < .05) by PG to 172 +/- 2 d compared with 182 +/- 4 d for controls. Average age at estrus did not differ (P > . 10) between PG and N+PG (177 +/- 2 d). Greater proportions of N+PG (82%; P < .001) and PG (65%; P < .001) gilts ovulated than controls (13%), but proportions did not differ between N+PG and PG (P > .10). The number of CL (20 +/- 2) was not affected by treatment and ranged from 2 to 71. There was no increase in ovarian cysts in response to treatment. Results indicated that norgestomet before PG600 did not enhance estrus expression or ovulation compared with PG600 alone, but use of PG600 increased the proportions of gilts that expressed estrus and ovulated compared with controls.
Knox
R V
RV
Department of Agriculture, Illinois State University, Normal 61790-5020, USA.
Tudor
K W
KW
D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D004971:Estrus / Q000187:drug effects*; D005260:Female; D006062:Gonadotropins / Q000008:administration & dosage / Q000494:pharmacology*; D010062:Ovulation Induction / Q000379:methods / Q000662:veterinary*; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*; D013552:Swine / Q000502:physiology*
D006062:Gonadotropins; D011282:Pregnenediones; D045167:Progesterone Congeners; C100284:norgestomet